oncology

Shire's oncology exit weighs on potential Takeda bid
Shire's oncology exit weighs on potential Takeda bid
Biopharma Dive
Shire
oncology
Takeda
M&A
Servier
Flag link:
Servier buys Shire’s oncology unit for $2.4B in the run-up to Takeda’s final buyout offer — if it makes one
Servier buys Shire’s oncology unit for $2.4B in the run-up to Takeda’s final buyout offer — if it makes one
Endpoints
Servier
Shire
Takeda
M&A
oncology
Flag link:
How Pfizer Plans to Move Into the Big Leagues for Cancer Treatment
How Pfizer Plans to Move Into the Big Leagues for Cancer Treatment
Motley Fool
cancer
oncology
Pfizer
Ibrance
breast cancer
Xtandi
prostate cancer
Bavencio
bladder cancer
Merkel cell carcinoma
lorlatinib
metastatic non-small cell lung cancer
talazoparib
metastatic breast cancer
Flag link:
Forget Remicade -- Here's How Johnson & Johnson Plans to Grow
Forget Remicade -- Here's How Johnson & Johnson Plans to Grow
Motley Fool
JNJ
Stelara
Zytiga
Darzalex
oncology
immunology
Flag link:
Beyond Flatiron: The Rising Power Of Oncology Clinical Data Companies
Beyond Flatiron: The Rising Power Of Oncology Clinical Data Companies
Forbes
oncology
Clinical Data
Flatiron Health
Roche
Flag link:
Accelerated Approval in Oncology: FDA Touts Successes, Responds to Criticism
Accelerated Approval in Oncology: FDA Touts Successes, Responds to Criticism
RAPS.org
drug approvals
FDA
oncology
PMRs
accelerated approvals
Flag link:
Gilead Sciences: The Oncology Company?
Gilead Sciences: The Oncology Company?
Motley Fool
Gilead Sciences
oncology
Kite Pharma
Cell Design Labs
Sangamo Therapeutics
Flag link:
The Deeply Human Core of Roche's $2.1B Tech Acquisition - And Why They Did It
The Deeply Human Core of Roche's $2.1B Tech Acquisition - And Why They Did It
Forbes
Roche
M&A
oncology
R&D
Flatiron Health
EHRs
Flag link:
Fresenius oncology drug plant slammed with new warning letter
Fresenius oncology drug plant slammed with new warning letter
Fierce Pharma
Fresenius
warnings
drug manufacturing
oncology
Flag link:
Oncology business to keep leading pharma market in 2018
Oncology business to keep leading pharma market in 2018
GoinPharma
oncology
Merck
Bristol-Myers Squibb
Pfizer
Roche
Flag link:
Roche Bets $1.7B More on Precision Oncology With Ignyta Deal
Roche Bets $1.7B More on Precision Oncology With Ignyta Deal
Xconomy
Roche
Ignyta
M&A
precision medicine
oncology
Flag link:
Novartis oncology CEO Bruno Strigini is calling it quits
Novartis oncology CEO Bruno Strigini is calling it quits
Endpoints
Novartis
oncology
Bruno Strigini
Flag link:
Yervoy inventor’s oncology startup Pionyr gets $62M for tumor-fighting tech
Yervoy inventor’s oncology startup Pionyr gets $62M for tumor-fighting tech
Endpoints
Yervoy
oncology
Pionyr
Flag link:
One big Novartis takeaway from Entresto's slow start? Heart failure doesn't work like oncology
One big Novartis takeaway from Entresto's slow start? Heart failure doesn't work like oncology
Fierce Pharma
Novartis
Entresto
drug launches
heart failure
oncology
Flag link:
Astellas innovation contest's second year yields bumper crop of creative cancer solutions
Astellas innovation contest's second year yields bumper crop of creative cancer solutions
Fierce Pharma
Astellas
innovation
oncology
Flag link:
Novartis to buy French cancer specialist AAA for $3.9 billion
Novartis to buy French cancer specialist AAA for $3.9 billion
Yahoo/Reuters
Novartis
M&A
France
Advanced Accelerator Application
radiopharmaceuticals
oncology
Flag link:
[forum discussion]What's up in Oncology?
[forum discussion]What's up in Oncology?
Cafepharma Message Boards
Merck
oncology
drug reps
Lynparza
Flag link:
Most new cancer meds haven't proved they can improve or extend lives: study
Most new cancer meds haven't proved they can improve or extend lives: study
Fierce Pharma
cancer
oncology
Merck
Keytruda
Roche
Tecentriq
Flag link:
Ipsen focuses on oncology to keep growing
Ipsen focuses on oncology to keep growing
GoInPharma
Ipsen
oncology
Xermelo
kidney cancer
Flag link:
Ramping back up on oncology, GSK takes an option on Adaptimmune’s TCR cancer drug
Ramping back up on oncology, GSK takes an option on Adaptimmune’s TCR cancer drug
Endpoints
GSK
oncology
Adaptimmune
TCR therapeutics
Flag link:

Pages